UNDERSTANDING THE BENEFITS OF COMT INHIBITION AND ONGENTYS® (OPICAPONE) CAPSULES FOR PATIENTS WITH PARKINSON'S DISEASE

This promotional educational activity is sponsored by Neurocrine Biosciences, Inc. and is not certified for CME credit. The speaker is a paid consultant of Neurocrine and the information to be presented is consistent with FDA guidelines.

PRESENTED BY

Paige Harris, NP APRN

Acute Care Nurse Practitioner
Neurology Consultants of Montgomery | Montgomery, AL
Montgomery, AL

DATE/TIME

Friday, 10/14/2022 06:00 pm Central

LOCATION

Renaissance Mobile Riverview Plaza Hotel
64 S. Water Street
Mobile Alabama 36602

Please RSVP to your Neurocrine Representative, Chris Zaragoza at czaragoza@neurocrine.com or (205) 864-5558 by 10/10/2022.

Ensuring the health and well-being of customers remains Neurocrine's highest priority and as such please refrain from attending a live program if you have experienced any of the following symptoms in the last 48 hours: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, been in close contact with a person with symptomatic laboratory confirmed COVID-19. Additionally please follow guidelines set forth by state and local agencies and the Centers for Disease Control and Prevention.

INDICATION & USAGE

ONGENTYS® (opicapone) capsules is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ONGENTYS is contraindicated in patients with:

- Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.
- Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

Please see additional Important Safety Information on the following page.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS & PRECAUTIONS

Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT)

Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT, regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT.

Falling Asleep During Activities of Daily Living and Somnolence

Patients treated with dopaminergic medications and medications that increase levodopa exposure, including ONGENTYS, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. If a patient develops daytime sleepiness or somnolence, consider discontinuing ONGENTYS or adjusting other dopaminergic or sedating medications and advise patients to avoid driving and other potentially dangerous activities.

Hypotension/Syncope

Monitor patients for hypotension and advise patients about the risk for syncope. If these adverse reactions occur, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure.

Dyskinesia

ONGENTYS potentiates the effects of levodopa which may result in dyskinesia or exacerbate pre-existing dyskinesia. Reducing the patient's levodopa dosage or the dosage of another dopaminergic drug may reduce dyskinesia that occurs during treatment with ONGENTYS.

Hallucinations and Psychosis

Consider stopping ONGENTYS if hallucinations or psychotic-like behaviors occur. Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS.

Impulse Control/Compulsive Disorders

Patients may experience intense urges (eg, gambling, sexual, spending money, binge eating) and the inability to control them. It is important for prescribers to specifically ask patients or their caregivers about the development of new or increased urges.

Re-evaluate the patient's current therapies for Parkinson's disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS.

Withdrawal-Emergent Hyperpyrexia and Confusion

A symptom complex resembling neuroleptic malignant syndrome (elevated temperature, muscular rigidity, altered consciousness, and autonomic instability) has been reported in association with rapid dose reduction or withdrawal of drugs that increase central dopaminergic tone. There were no reports of neuroleptic malignant syndrome in ONGENTYS controlled clinical studies. When discontinuing ONGENTYS, monitor patients and consider adjustment of other dopaminergic therapies as needed.

ADVERSE REACTIONS

The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, and weight decreased.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see ONGENTYS full Prescribing Information or visit www.neurocrine.com/assets/ONGENTYS-PI.pdf.

As required by the U.S. Sunshine Act, Neurocrine will track and report to government agencies the cost of meals provided to individual health care professionals in connection with attendance at this promotional educational activity. This information will be made publicly available. If you wish to not partake in the meal, please "opt out" of the meal when signing in. Neurocrine will not provide alcohol at this program.

Ongentys® (opicapone) capsules

under license from Bial

NEUROCRINE® BIOSCIENCES